No new safety concerns emerged in the 20-week extension of the phase 3 VERIFY study.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/hematocrit-phlebotomy-benefits-seen-rusfertide-pv-2025a1000y84?src=rss
Author :
Publish date : 2025-12-07 19:08:00
Copyright for syndicated content belongs to the linked Source.